anaxirone profile

Anaxirone, a selective 5-HT2C receptor agonist, has been studied for its potential therapeutic effects in various conditions, including anxiety, depression, obesity, and drug addiction. Its unique pharmacological profile suggests that it might modulate neurotransmitter release in the brain, leading to alterations in mood, appetite, and cognitive function. The compound's synthesis involves complex chemical reactions and requires specialized expertise. While promising, research on anaxirone is still ongoing, and its precise mechanisms of action and potential side effects are being investigated.'

anaxirone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	71218
CHEMBL ID	2105991
SCHEMBL ID	93704
MeSH ID	M0122067

Synonym
tgu
triglycidylurazol
anaxirone
nsc-332488
1,4-triazolidine-3,5-dione, 1,2,4-tris(oxiranylmethyl)-
77658-97-0
1,4-triazolidine-3,5-dione, 1,2,4-tri(oxiranylmethyl)-
1,4-triazolidine-3,5-dione, 1,2,4-tris(oxiranylmethyl)-, .alpha.-isomer
nsc332488
triglycidylurazole
tris(2,3-epoxypropyl)bicarbamimide
anaxironum [latin]
nsc 332488
1,2,4-triazolidine-3,5-dione, 1,2,4-tri(oxiranylmethyl)-
anaxirone [inn]
n,n',n''-triglycidyl-1,2,4-triazolidine-3,5-dione
1,2,4-triazolidine-3,5-dione, 1,2,4-tris(oxiranylmethyl)-
anaxirona [spanish]
1,2,4-tris(oxiranylmethyl)-1,2,4-triazolidine-3,5-dione
1,2,4-triglycidylurazol
einecs 278-745-8
1,2,4-tris(oxiran-2-ylmethyl)-1,2,4-triazolidine-3,5-dione
CHEMBL2105991
anaxirona
36r61y789t ,
unii-36r61y789t
anaxironum
anaxirone [mart.]
SCHEMBL93704
triglycidyl urazole
1,2,4-triglycidyl urazole
ZTXDHEQQZVFGPK-UHFFFAOYSA-N
DTXSID10868451
1,2,4-tris[(oxiran-2-yl)methyl]-1,2,4-triazolidine-3,5-dione
Q27256591

Excerpt	Relevance	Reference
" We test new structures in 20 well-selected human tumor xenografts and in the P388 mouse leukemia in dose-response relationships."	( Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development. Bieser, W; Fiebig, HH; Henss, H; Lohr, GW; Schmid, JR, 1987)	0.27

Bioassays (19)

Assay ID	Title	Year	Journal	Article
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	20 (90.91)	18.7374
1990's	2 (9.09)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (4.35%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	22 (95.65%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
sarcosine cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis	2.37	2	0	N-alkylglycine zwitterion; N-alkylglycine; N-methyl-amino acid; N-methylglycines	Escherichia coli metabolite; glycine receptor agonist; glycine transporter 1 inhibitor; human metabolite; mouse metabolite
busulfan [no description available]	1.97	1	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
sarcosine dithiocarbamate sarcosine dithiocarbamate: protects against toxicity of alkylating agents	2.37	2	0
pamidronate [no description available]	1.96	1	0	phosphonoacetic acid
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	1.97	1	0	mitomycin	alkylating agent; antineoplastic agent
diethylnitrosamine Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.	1.97	1	0	nitrosamine	carcinogenic agent; hepatotoxic agent; mutagen
ribavirin Rebetron: Rebetron is tradename	1.97	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	5.79	22	1	1,2,3-triazole
mafosfamide mafosfamide: RN given refers to cis-(+-)-isomer	2.37	2	0
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	1.96	1	0	divalent inorganic anion; phosphite ion
tiazofurin tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).	1.97	1	0	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug

Condition	Relationship Strength	Studies	Trials
Benign Neoplasms [description not available]	3.06	5	0
Experimental Neoplasms [description not available]	2.37	2	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.06	5	0
Leukocytopenia [description not available]	4.45	5	1
Metastase [description not available]	3.77	2	1
Thrombopenia [description not available]	4.45	5	1
Colorectal Cancer [description not available]	8.37	1	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	4.45	5	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	3.77	2	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	4.45	5	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.37	1	1
Cholera Infantum [description not available]	1.97	1	0
Blood Diseases [description not available]	2.38	2	0
Hematologic Diseases Disorders of the blood and blood forming tissues.	2.38	2	0
Experimental Hepatoma [description not available]	2.37	2	0
Carcinoma, Oat Cell [description not available]	2.37	2	0
Cancer of Lung [description not available]	2.66	3	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.66	3	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	2.37	2	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	1.96	1	0
Malignant Melanoma [description not available]	1.97	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.97	1	0
Adenocarcinoma, Basal Cell [description not available]	2.37	2	0
Carcinoma, Epidermoid [description not available]	1.97	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.37	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	1.97	1	0
Cancer of Ovary [description not available]	1.97	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1.97	1	0
Sarcoma, Epithelioid [description not available]	1.97	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	1.97	1	0
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	1.97	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	1.96	1	0
Cancer of Kidney [description not available]	2.37	2	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.37	2	0
Breast Cancer [description not available]	1.97	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1.97	1	0
Adenocarcinoma Of Kidney [description not available]	1.97	1	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	1.97	1	0
Bone Cancer [description not available]	1.96	1	0
Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)	1.96	1	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	1.96	1	0
Periphlebitis Periphlebitis is inflammation of the outer coat of a vein or of tissues surrounding the vein.	1.96	1	0
Phlebitis Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).	1.96	1	0

anaxirone

Description

Cross-References

Synonyms (35)

Research Excerpts

Dosage Studied

Bioassays (19)

Research

Studies (22)

Market Indicators

Research Demand Index: 11.05

Study Types

anaxirone

Description

Cross-References

Synonyms (35)

Research Excerpts

Dosage Studied

Bioassays (19)

Research

Studies (22)

Market Indicators

Research Demand Index: 11.05

Study Types

Related Drugs (11)

Related Conditions (43)